Quebec-based Repare Therapeutics has raised $68M in Series A funding in a round led by MPM Capital and Versant Ventures. The round also saw participation from BDC Healthcare, Celgene and the Fonds de solidarité FTQ. Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
